NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

BACKGROUND: NTP42 is a novel antagonist of the thromboxane prostanoid receptor (TP), currently in development for the treatment of pulmonary arterial hypertension (PAH). PAH is a devastating disease with multiple pathophysiological hallmarks including excessive pulmonary vasoconstriction, vascular r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mulvaney, Eamon P., Reid, Helen M., Bialesova, Lucia, Bouchard, Annie, Salvail, Dany, Kinsella, B. Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132963/
https://www.ncbi.nlm.nih.gov/pubmed/32252727
http://dx.doi.org/10.1186/s12890-020-1113-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132963/
https://www.ncbi.nlm.nih.gov/pubmed/32252727
http://dx.doi.org/10.1186/s12890-020-1113-2

Ejemplares similares